| 10/30/2026 15:30 |
Summary of Consolidated Financial Results for the Six Months Ended September 30, 2026 [IFRS] |
| 10/30/2026 15:30 |
Sumitomo Pharma Announces Variances Between H1 FY2026 Financial Forecasts and Actual Results and Revisions to FY2026 Financial Forecasts |
| 10/30/2026 15:30 |
Sumitomo Pharma Announces Revision of Its Year-End Dividend Forecast for the Fiscal Year Ending March 31, 2027 |
| 10/30/2026 15:30 |
Presentation Material (Conference on Q2 FY2026 Financial Results |
| 10/30/2026 15:30 |
Supplementary Financial Data (IFRS) for the Six Months Ended September 30, 2026 |
| 10/27/2026 09:08 |
Sumitomo Pharma America Announces Enzomenib (DSP-5336) Receives FDA Breakthrough Therapy Designation for Treatment of R/R KMT2A-Rearranged Acute Leuke |
| 08/31/2026 11:00 |
Sumitomo Pharma Selected as a Constituent of Five GPIF-Adopted ESG Indexes |
| 08/26/2026 16:00 |
Sumitomo Pharma Selected as a Constituent of the JPX Prime 150 Index |
| 08/13/2026 09:15 |
Sumitomo Pharma America Announces First Patient Receives Treatment in Phase 1/2a Study for Investigational Therapy DSP-3077 for Retinitis Pigmentosa |
| 08/12/2026 08:30 |
Regarding a Report Concerning Sumitomo Pharma (The Company's Views on the GCR August 7 Report) |
| 08/04/2026 14:46 |
Regarding a Report Concerning Sumitomo Pharma |
| 07/31/2026 15:30 |
Supplementary Financial Data (IFRS) for the Three Months Ended June 30, 2026 |
| 07/31/2026 15:30 |
Presentation Material (Conference on Q1 FY2026 Financial Results) |
| 07/31/2026 15:30 |
Summary of Consolidated Financial Results for the Three Months Ended June 30, 2026 [IFRS] |
| 07/01/2026 19:00 |
Corporate Governance Report |
| 06/25/2026 15:30 |
Matters Concerning Controlling Shareholders, Etc. |
| 06/16/2026 10:00 |
Sumitomo Pharma America Announces Encouraging Clinical and Translational Data at EHA 2026 |
| 06/02/2026 10:40 |
[Delayed]Corporate Governance Report |
| 06/02/2026 10:00 |
Sumitomo Pharma America Presents First Clinical Data for SMP-3124LP, an Investigational PEGylated Liposome CHK1 Inhibitor, at ASCO 2026 |
| 05/22/2026 16:40 |
Notice Regarding Results of Capital Increase by way of Third-Party Allotment (Not Implemented) |
| 05/13/2026 13:00 |
Presentation Material Conference on FY2025 Financial Results |
| 05/13/2026 13:00 |
Supplementary Financial Data (IFRS) for the Year Ended March 31, 2026 |
| 05/13/2026 13:00 |
Summary of Consolidated Financial Results for the Year Ended March 31, 2026 [IFRS] |
| 04/27/2026 11:30 |
Notice regarding Withdrawal of Shelf Registration Statement for Issuance of New Shares |
| 04/20/2026 17:30 |
Notice Regarding Determination of Issue Price, Selling Price and Other Matters |
| 04/08/2026 16:00 |
Notice Regarding Issuance of New Shares and Secondary Offering of Shares |
| 04/08/2026 16:00 |
Notice Regarding Refinancing of Existing Borrowings through a Bridge Loan |
| 03/02/2026 15:41 |
Presentation Material (Boost 2028 - Accelerating Strong Sumitomo Pharma -) |
| 03/02/2026 15:41 |
Sumitomo Pharma Announces Boost 2028 - Accelerating Strong Sumitomo Pharma - |
| 03/02/2026 15:41 |
Announcement of Filing of Shelf Registration Statement for Issuance of New Shares |
| 03/02/2026 15:41 |
Sumitomo Pharma Announces Revisions to Its Financial Forecasts |
| 02/17/2026 15:00 |
Publication of Materials from the R&D Meeting for Analysts, Investors, and Media |
| 02/13/2026 17:20 |
Regarding the Scheduled Review in Japan of the Allogeneic iPS Cell-Derived dopaminergic neural progenitor cells (AMCHEPRY) |
| 01/30/2026 15:30 |
Presentation Material (Conference on Q3 FY2025 Financial Results) |
| 01/30/2026 15:30 |
Supplementary Financial Data (IFRS) for the Third Quarter of the Year Ending March 31, 2026 |
| 01/30/2026 15:30 |
Summary of Consolidated Financial Results for the Nine Months Ended December 31, 2025 [IFRS] |
| 12/15/2025 11:00 |
Sumitomo Pharma Selected as Highest Rating A-List Company by CDP for Two Consecutive Years in the Category of Climate Change in the CDP 2025 |
| 12/09/2025 13:00 |
Sumitomo Pharma America Presents New Investigational Data on Enzomenib and Nuvisertib at the ASH 2025 |
